FDA pulmonary division director
Executive Summary
Badrul Chowdhury, MD/PhD, named permanent director of CDER's Division of Pulmonary & Allergy Drug Products. He has served as acting director since July 2002 following the promotion of Robert Meyer, MD, to Office of Drug Evaluation II director (1"The Pink Sheet" July 8, 2002, In Brief)...
You may also be interested in...
FDA Pulmonary Division acting director
Badrul Chowdhury, MD/PhD, appointed acting director of FDA's CDER Division of Pulmonary & Allergy Drug Products. Chowdhury, a team leader in the division for three years and a member of the Clarinex review team, succeeds Robert Meyer, MD, who became Office of Drug Evaluation II director in June (1"The Pink Sheet" June 3, p. 9)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.